Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 19/20 | 0.91 |
| ▸ | CLK3 | P49761 | 19/20 | 0.91 |
| ▸ | DYRK1A | Q13627 | 19/20 | 0.91 |
| ▸ | CLK1 | P49759 | 1/20 | 0.85 |
| ▸ | GSK3B | P49841 | 1/20 | 0.85 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.85 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.85 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.85 |
| ▸ | WNT1 | P04628 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273932 | 0.95 | CLK2 (1.00) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15306693 | 0.94 | CLK2 (0.88) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15301680 | 0.93 | CLK2 (1.00) | CLK2CLK3DYRK1ACLK1GSK3B | |
| Lorecivivint SCHEMBL30934911 | 0.92 | CLK2 (1.00) | CLK2CLK3DYRK1ACLK1GSK3B | |
| Lorecivivint SCHEMBL29383887 | 0.92 | CLK2 (1.00) | CLK2CLK3DYRK1ACLK1GSK3B | |
| Lorecivivint SCHEMBL15302155 | 0.92 | CLK2 (1.00) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL12010077 | 0.91 | CLK2 (0.84) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15301605 | 0.91 | CLK2 (0.82) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15306714 | 0.91 | CLK2 (0.81) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15306576 | 0.90 | CLK2 (0.86) | CLK2CLK3DYRK1ACLK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667632-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667632-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210292319-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667632-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof | IL33, IL4, IL1B | CLK2 2101/4885CLK3 1876/4885DYRK1A 3081/4885 |
| US-20210292319-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOF | IL33, IL4, IL1B | CLK2 2101/4885CLK3 1876/4885DYRK1A 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.